Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Provides Form 10-K Filing UpdateApril 15, 2021

Emmaus announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company’s 2020 Annual Report on Form 10-K and related earnings release.

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer DrugMarch 02, 2021

Emmaus Life Sciences, Inc., announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos.

Emmaus Life Sciences Reports Increase in Sales Volume in 2020January 27, 2021

Emmaus Life Sciences, Inc., reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.

Emmaus Life Sciences Reports Annual Financial Results for 2019 and Provides Business ReviewJanuary 25, 2021

Emmaus Life Sciences, Inc., reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.

Michigan Revises Prior Authorization Criteria for Endari®December 10, 2020

Emmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.